CN117018108A - 一种高效缓解疼痛的药物组合物及其制备方法和其应用 - Google Patents
一种高效缓解疼痛的药物组合物及其制备方法和其应用 Download PDFInfo
- Publication number
- CN117018108A CN117018108A CN202311060777.2A CN202311060777A CN117018108A CN 117018108 A CN117018108 A CN 117018108A CN 202311060777 A CN202311060777 A CN 202311060777A CN 117018108 A CN117018108 A CN 117018108A
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- pain
- blood
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 98
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims description 24
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 26
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 26
- 239000009136 dragon's blood Substances 0.000 claims abstract description 26
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 25
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 25
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 25
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 25
- 239000004863 Frankincense Substances 0.000 claims abstract description 25
- 235000005206 Hibiscus Nutrition 0.000 claims abstract description 24
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 claims abstract description 24
- 244000284380 Hibiscus rosa sinensis Species 0.000 claims abstract description 24
- 240000004824 Trimezia steyermarkii Species 0.000 claims abstract description 24
- 241000131329 Carabidae Species 0.000 claims abstract description 23
- 235000009467 Carica papaya Nutrition 0.000 claims abstract description 23
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229910052802 copper Inorganic materials 0.000 claims abstract description 23
- 239000010949 copper Substances 0.000 claims abstract description 23
- 244000306301 Caesalpinia sappan Species 0.000 claims abstract description 22
- 235000015162 Caesalpinia sappan Nutrition 0.000 claims abstract description 22
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 22
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 22
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 22
- 244000223014 Syzygium aromaticum Species 0.000 claims abstract description 20
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims abstract description 20
- 244000048199 Hibiscus mutabilis Species 0.000 claims abstract description 16
- 235000003973 Hibiscus mutabilis Nutrition 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 40
- 241000382455 Angelica sinensis Species 0.000 claims description 24
- 241000219173 Carica Species 0.000 claims description 22
- 241001106477 Paeoniaceae Species 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 17
- 241000133430 Tinospora Species 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 238000000227 grinding Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 244000273928 Zingiber officinale Species 0.000 claims description 4
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 4
- 235000008397 ginger Nutrition 0.000 claims description 4
- 235000021419 vinegar Nutrition 0.000 claims description 4
- 239000000052 vinegar Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 240000003428 Tinospora crispa Species 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000002035 prolonged effect Effects 0.000 abstract description 3
- 230000004044 response Effects 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 240000006432 Carica papaya Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 61
- 210000004369 blood Anatomy 0.000 description 61
- 210000002435 tendon Anatomy 0.000 description 23
- 208000014674 injury Diseases 0.000 description 21
- 230000017531 blood circulation Effects 0.000 description 18
- 230000001737 promoting effect Effects 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 17
- 230000003213 activating effect Effects 0.000 description 16
- 230000006378 damage Effects 0.000 description 16
- 208000027418 Wounds and injury Diseases 0.000 description 15
- 208000006820 Arthralgia Diseases 0.000 description 14
- 229940079593 drug Drugs 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000008961 swelling Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 230000009471 action Effects 0.000 description 8
- 230000002040 relaxant effect Effects 0.000 description 8
- 210000003127 knee Anatomy 0.000 description 7
- 239000002023 wood Substances 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 208000010392 Bone Fractures Diseases 0.000 description 5
- 208000026137 Soft tissue injury Diseases 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 230000008733 trauma Effects 0.000 description 5
- 241001489978 Eupolyphaga Species 0.000 description 4
- 206010017076 Fracture Diseases 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 229960001259 diclofenac Drugs 0.000 description 4
- 210000000629 knee joint Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 3
- 206010052443 Myofascitis Diseases 0.000 description 3
- 208000024288 Rotator Cuff injury Diseases 0.000 description 3
- 206010039227 Rotator cuff syndrome Diseases 0.000 description 3
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 208000036319 cervical spondylosis Diseases 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 208000005801 spondylosis Diseases 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010050031 Muscle strain Diseases 0.000 description 2
- 206010033425 Pain in extremity Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 206010034464 Periarthritis Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000000281 joint capsule Anatomy 0.000 description 2
- 208000024765 knee pain Diseases 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 206010060968 Arthritis infective Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000218993 Begonia Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010061223 Ligament injury Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010053156 Musculoskeletal discomfort Diseases 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 244000251905 Pseudocydonia sinensis Species 0.000 description 1
- 235000017831 Pseudocydonia sinensis Nutrition 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 208000018286 Shoulder injury Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 241001092391 Sorbus Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000021945 Tendon injury Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241001643425 Tinospora sinensis Species 0.000 description 1
- 206010049514 Traumatic fracture Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 241000830536 Tripterygium wilfordii Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 210000004439 collateral ligament Anatomy 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960002849 glucosamine sulfate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025005 lumbar spinal stenosis Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000008345 mountainash Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 208000005198 spinal stenosis Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000015398 thunder god vine Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种高效缓解疼痛的药物组合物,以重量份计,组合物中含有当归10‑30份、木瓜10‑30份、赤芍10‑30份、乳香10‑30份、土鳖虫10‑30份、苏木5‑20份、红花5‑20份、血竭0.1‑5份、丁香5‑20份、(木)芙蓉叶20‑40份、金果榄20‑40份、没药10‑25份和煅自然铜20‑40份。本发明的药物组合物具有起效快、治疗有效率高(≥96%)和显效率高(≥65%)、复发率低、复发间隔周期延长、安全有效、患者依从性好等优点。
Description
技术领域
本发明属于生物医药领域,具体涉及一种高效缓解疼痛的药物组合物及其制备方法和其应用。
背景技术
各种急性损伤、慢性劳损、风寒湿邪侵袭等,均会造成人体皮肤、皮下浅深筋膜、肌肉、肌腱、韧带、关节囊、椎间盘等组织的病理损害和疼痛,病因病机主要包括外伤或劳损所致的气血阻滞、运行不畅、不通则痛等。骨折、脱位、软组织损伤后期的局部疼痛为常见的骨科疾病,多因外伤或慢性劳损导致经络气血受损、循环功能欠佳所致。颈肩腰腿痛、骨关节炎、肌筋膜炎等疾病,主要表现为患处疼痛、活动受限、屈伸不利等,且疼痛及活动受限呈进行性加重,严重影响患者的生命健康及生活工作质量,病情严重者最终丧失劳动力,部分患者不得不接受手术治疗,给患者及家庭带来经济负担。
非手术治疗骨科疾病及其疼痛的主要方法包括物理疗法和药物治疗。物理疗法包括针灸、热敷、超短波、电磁波等,但存在治疗效果不显著、疗程和耗时长、患者依从性差等缺陷。药物治疗包括使用非甾体类消炎药(如塞来昔布、布洛芬、吲哚美辛、双氯芬酸二乙胺乳胶剂软膏等)缓解疼痛,使用硫酸氨基葡萄糖、硫酸软骨素等延缓关节退变病程,关节腔内及局部注射透明质酸钠、利多卡因、糖皮质激素等,以及使用神经营养药物、细胞因子、基因调控疗法等,但存在药物起效慢、病程长、关节感染风险、胃肠道、中枢神经系统、肾脏、过敏、复发率高、复发间隔周期短等问题。为此,急需研发高效缓解疼痛且安全有效的药物组合物,以满足临床需求。
发明内容
本发明的目的在于提供一种高效缓解疼痛的药物组合物,以重量份计,组合物中含有当归10-30份、木瓜10-30份、赤芍10-30份、乳香10-30份、土鳖虫10-30份、苏木5-20份、红花5-20份、血竭0.1-5份、丁香5-20份、(木)芙蓉叶20-40份、金果榄20-40份、没药10-25份和煅自然铜20-40份。
本发明的优选技术方案,以重量份计,组合物中含有当归15-25份、木瓜15-25份、赤芍15-25份、乳香15-25份、土鳖虫15-25份、苏木8-15份、红花8-15份、血竭0.5-3份、丁香8-15份、(木)芙蓉叶25-35份、金果榄25-35份、没药15-20份和煅自然铜25-35份。
本发明的优选技术方案,以重量份计,组合物中含有当归20份、木瓜20份、赤芍20份、乳香20份、土鳖虫20份、苏木10份、红花10份、血竭1份、丁香10份、(木)芙蓉叶30份、金果榄30份、没药18份和煅自然铜30份。
本发明的优选技术方案,以重量份计,组合物中含有当归15份、木瓜15份、赤芍15份、乳香15份、土鳖虫15份、苏木5份、红花5份、血竭1份、丁香5份、(木)芙蓉叶20份、金果榄10份、没药15份和煅自然铜20份。
本发明的优选技术方案,以重量份计,组合物中含有当归30份、木瓜30份、赤芍30份、乳香30份、土鳖虫20份、苏木10份、红花10份、血竭1份、丁香10份、(木)芙蓉叶30份、金果榄30份、没药18份和煅自然铜30份。
本发明采用辨证施治法科学配伍药物组合物,取当归补血活血之功,协同利用赤芍、木瓜、红花、苏木等具有活血化瘀、舒筋活络、通经止痛,活血舒筋、通经散瘀、达行气血、舒筋脉、散瘀血等功效的组分,并协同利用乳香、没药、土鳖虫、血竭、(木)芙蓉叶、金果榄、煅自然铜等的活血定痛、破血逐瘀、软坚散结、凉血消肿等具有活血化瘀、接骨续筋、祛风除湿、散寒止痛等功效的组分,有效防治筋聚筋僵,显著改善软组织损伤、筋聚筋僵、颈肩腰腿等部位慢性劳损及损伤后期遗留疼痛或疼痛不适等症状,并具有起效快、治疗有效率高、复发率低、复发间隔周期延长、容易配制、使用方便、安全有效、患者依从性好等优点。
当归为“血家之圣药”,血中气药,综一身之用,和血补血活血止痛,使气血固足,方气行血活,助瘀散坚消。《本草正义》有言:“归身主守,补固有功;归尾主通,逐瘀自验”。《雷公炮制药性论》亦言:“当归头,止血而上行;身,养血而守中;梢,破血而下流;全,活血而不走”。
赤芍为毛茛科植物赤芍或川赤芍的干燥根,春秋二季采挖,除去根茎、须根及泥沙后晒干。性苦、微寒,归肝经,可益气行血,破瘀散恶血,通顺血脉。《本草求真》记载,“赤芍与白芍主治略同…赤则止有散邪行血之意…赤则能于血中活滞…用此则能凉血逐瘀”。
木瓜为蔷薇科植物贴梗海棠的干燥近成熟果实,性温,味酸,归肝脾经,功在舒筋活络,亦兼化湿,为筋脉拘挛者之要药,可治转筋挛痛、湿痹拘挛、腰膝关节酸重疼痛。筋脉为病,木瓜可舒肝和脾,舒利筋脉。《本草新编》称木瓜为“入肝益筋之品,养血卫脉之味”。
红花秉辛散温通之性,能活血祛瘀,通调经脉;长于行血,专行血瘀,治外伤陈疾等瘀血症。
苏木活血通经,祛瘀止痛,能行积血;少用可活血养血,重用则破血消癥。
乳香辛香发散温通,具有活血化瘀、止痛、活血舒筋、行气散滞、消肿生肌等功效,可助益外用药力之透达。
没药主破癥结宿血,破血止痛,消肿生肌。善活血,为外伤科要药,治内外瘀滞诸痛及痛疽肿痛所常用。《雷公炮制药性解》:“没药与乳香同功,大抵血滞则气壅淤,气壅淤则经络满急,故痛且肿,得没药以宣通气血,宜其治也”。
土鳖虫(又称土元、地鳖)具有善化瘀血、专破癥瘀、最补损伤等功效,用于诸类损伤,治骨折筋伤后期,筋骨软弱无力者,有续筋接骨、疗伤止痛之效。
血竭味甘、咸,性平,归心、肝经。其走血软坚,行中有止,能活血散瘀而止痛,治跌打损伤血瘀诸证。《玉楸药解》有言:“血竭破瘀血,癥瘕积块、跌扑停瘀皆良。破瘀行血,止痛续伤”。血竭亦可用于外伤出血,溃疡不敛,有止血生肌之效。
(木)芙蓉叶,性平味辛,有凉血解毒、消肿止痛之功。外用适于痈疽肿毒、烫伤、跌打损伤等证。《玉楸药解》言:“木芙蓉,清利消散,善败肿毒,一切疮疡,大有捷效,涂饮俱善”。
金果榄为植物青牛胆的干燥块根,苦寒之品,有清热解毒止痛之功,可用于诸般痈疽疔疮之流。《药性考》中对其外用记载:“疽痈发背,焮赤疔瘯,蛇蝎虫伤,磨涂”。
煅自燃铜,散瘀止痛,接骨疗伤,补伤续绝,行瘀消肿。用于跌扑骨折、瘀阻肿痛等证。其可行血化滞、散瘀止痛,为伤科要药。
本发明的药物组合物取乳香、没药的活血行血、破瘀止痛之功,宣通气血,透达药力;取土元、血竭的活血之余,专破癥瘀,走血软坚,除陈疾之瘀血,使血行筋舒;取(木)芙蓉叶、金果榄的凉血清热、清利消散之功用,使全方性味更取中正平和;取煅自然铜为补伤续绝之伤科要药,陈旧性损伤日久,虽非骨折筋绝,但久失濡养必有筋骨损伤,故亦自然铜、土元以疗伤止痛。既佐君臣活血舒筋化瘀之功,并针对陈旧损伤之沉疴,强化破癥软坚、补伤续绝之用,并注意药性调和,保护外用之肌肤。丁香取其辛温透散之性,温通助阳,助诸药之功透达病所。
本发明的优选技术方案,称取所需量的组分,将其均匀混合后,研磨为药物组合物细粉,即得,优选药物组合物细粉为150目-200目。
本发明的优选技术方案,将制得的药物组合物细粉临用前用溶剂调成膏剂或糊剂,将制得的膏剂或糊剂涂抹在患者痛处或患处,依次用柔和的摩法、推法、掌按揉法的任一种或其组合,按摩3-5min后,再用透明薄膜覆盖药物15-20min,1次/d,20~30min/次,其中,所述溶剂选自水、姜汁、醋、白酒的任一种。
本发明的优选技术方案,药物组合物细粉:溶剂的质量体积比为1:10-20;
本发明的优选技术方案,所述组合物为外用制剂。
本发明的目的在于提供一种高效缓解疼痛的药物组合物的制备方法,以重量份计,组合物中含有当归10-30份、木瓜10-30份、赤芍10-30份、乳香10-30份、土鳖虫10-30份、苏木5-20份、红花5-20份、血竭0.1-5份、丁香5-20份、(木)芙蓉叶20-40份、金果榄20-40份、没药10-25份和煅自然铜20-40份,其制备包括下述步骤:将所需量的组分均匀混合后,研磨为细粉,即得。
本发明的优选技术方案,以重量份计,组合物中含有当归15-25份、木瓜15-25份、赤芍15-25份、乳香15-25份、土鳖虫15-25份、苏木8-15份、红花8-15份、血竭0.5-3份、丁香8-15份、(木)芙蓉叶25-35份、金果榄25-35份、没药15-20份和煅自然铜25-35份。
本发明的优选技术方案,以重量份计,组合物中含有当归20份、木瓜20份、赤芍20份、乳香20份、土鳖虫20份、苏木10份、红花10份、血竭1份、丁香10份、(木)芙蓉叶30份、金果榄30份、没药18份和煅自然铜30份。
本发明的优选技术方案,以重量份计,组合物中含有当归15份、木瓜15份、赤芍15份、乳香15份、土鳖虫15份、苏木5份、红花5份、血竭1份、丁香5份、(木)芙蓉叶20份、金果榄10份、没药15份和煅自然铜20份。
本发明的优选技术方案,以重量份计,组合物中含有当归30份、木瓜30份、赤芍30份、乳香30份、土鳖虫20份、苏木10份、红花10份、血竭1份、丁香10份、(木)芙蓉叶30份、金果榄30份、没药18份和煅自然铜30份。
本发明的优选技术方案,药物组合物细粉为150目-200目。
本发明的优选技术方案,将制得的药物组合物细粉临用前用溶剂调成膏剂或糊剂,将制得的膏剂或糊剂涂抹在患者痛处或患处,依次用柔和的摩法、推法、掌按揉法的任一种或其组合,按摩3-5min后,再用透明薄膜覆盖药物15-20min,1次/d,20~30min/次,其中,所述溶剂选自水、姜汁、醋、白酒的任一种。
本发明的优选技术方案,药物组合物细粉:溶剂的质量体积比为1:10-20;
本发明的优选技术方案,所述组合物为外用制剂。
本发明的另一目的在于提供本发明的药物组合物用于制备防治或缓解疼痛或疼痛不适所致的相关病症或其并发症的药物中的应用。
本发明的优选技术方案,所述疼痛选自痹症、软组织损伤所致疼痛,颈肩腰腿部位的慢性劳损所致疼痛,急性外伤或慢性劳损所致疼痛,风寒湿邪侵袭造成的人体皮肤、皮下浅深筋膜、肌肉、肌腱、韧带、关节囊、椎间盘的病理损害或损伤后遗症,骨折、脱位、关节痛、颈肩腰腿痛、骨关节炎、肌筋膜炎的任一种或其并发症。
本发明的优选技术方案,所述痹症选自肩痹症、腰痹症、膝痹中的任一种。
本发明的优选技术方案,所述肩痹症选自肩周炎、肩袖损伤的任一种或其并发症所致的肩痹症。
本发明的优选技术方案,所述腰痹症选自腰椎间盘突出症、腰椎管狭窄症、腰肌劳损的的任一种或其并发症所致的腰痹症。
本发明的优选技术方案,所述疼痛不适选自患处疼痛、活动受限、腰膝酸软、晨僵、肢体酸胀、屈伸不利、体倦乏力中的任一种。
本发明的优选技术方案,根据患者的病情、用药、年龄、性别、病痛类型等因素选择合适的用量和疗程。
本发明的优选技术方案,根据病变部位疼痛面积大小确定涂抹的药物组合物用量。
本发明的优选技术方案,药物组合物的用量为50-80g。
本发明的优选技术方案,将制得的药物组合物细粉临用前用溶剂调成膏剂或糊剂,将制得的膏剂或糊剂涂抹在患者痛处或患处,依次用柔和的摩法、推法、掌按揉法的任一种或其组合,按摩3-5min后,再用透明薄膜覆盖药物15-20min,1次/d,20~30min/次,其中,所述溶剂选自水、姜汁、醋、白酒的任一种。
本发明的优选技术方案,药物组合物细粉:溶剂的质量体积比为1:10-20;
本发明的优选技术方案,所述组合物为外用制剂。
除非另有说明,本发明涉及液体与液体之间的百分比时,所述的百分比为体积/体积百分比;本发明涉及液体与固体之间的百分比时,所述百分比为体积/重量百分比;本发明涉及固体与液体之间的百分比时,所述百分比为重量/体积百分比;其余为重量/重量百分比。
与现有技术相比,本发明具有下述有益效果:
1、本发明的药物组合物辨证施治法科学配伍,取当归补血活血之功,协同利用赤芍、木瓜、红花、苏木等具有活血化瘀、舒筋活络、通经止痛,活血舒筋、通经散瘀、达行气血、舒筋脉、散瘀血等功效的组分,并协同利用乳香、没药、土鳖虫、血竭、(木)芙蓉叶、金果榄、煅自然铜等的活血定痛、破血逐瘀、软坚散结、凉血消肿等具有活血化瘀、接骨续筋、祛风除湿、散寒止痛等功效的组分,有效防治筋聚筋僵,显著改善软组织损伤、筋聚筋僵、颈肩腰腿等部位慢性劳损及损伤后期遗留疼痛或疼痛不适等症状,且显著降低疼痛复发率,显著延长疼痛复发间隔周期,并具有起效快、治疗有效率高(≥96%)和显效率高(≥65%)、复发率低、复发间隔周期延长、容易配制、使用方便、安全有效、患者依从性好等优点。
2.本发明的药物组合物的制备药材具有来源广泛易得,制备操作简便,成本更优,适用于工业化生产等优点。
具体实施方式
下面结合具体实施例对本发明的详细内容做进一步解释和描述,但并不以此限制本发明的保护范围。
实施例1本发明药物组合物的制备
组合物的组成:当归20份、木瓜20份、赤芍20份、乳香20份、土鳖虫20份、苏木10份、红花10份、血竭1份、丁香10份、(木)芙蓉叶30份、金果榄30份、没药18份、煅自然铜30份。
组合物的制备:称取所需量的组分,将其均匀混合后,研磨为150目-200目细粉,即得。
实施例2本发明药物组合物的制备
组合物的组成:当归15份、木瓜15份、赤芍15份、乳香15份、土鳖虫15份、苏木5份、红花5份、血竭1份、丁香5份、(木)芙蓉叶20份、金果榄10份、没药15份、煅自然铜20份。
组合物的制备:称取所需量的组分,将其均匀混合后,研磨为150目-200目细粉,即得。
实施例3本发明药物组合物的制备
组合物的组成:当归30份、木瓜30份、赤芍30份、乳香30份、土鳖虫20份、苏木10份、红花10份、血竭1份、丁香10份、(木)芙蓉叶30份、金果榄30份、没药18份、煅自然铜30份。
组合物的制备:称取所需量的组分,将其均匀混合后,研磨为150目-200目细粉,即得。
试验例1本发明药物组合物用于缓解疼痛的作用研究
随机选取于2020年1月至2022年12月在东方医院骨科门诊就诊患者255例,将其分为治疗组和对照组。两组患者的年龄、病程等一般资料比较差异无统计学意义(P>0.05)。
治疗组患者220例,包括男89例,女131例;年龄最小35岁,最大78岁,平均年龄56.73±5.81岁;病史最长8年,最短3个月,平均病程8.51±7.93月,包括肩痹症(肩周炎、肩袖损伤)46例,颈椎病32例,腰痹症(腰椎间盘突出症、腰椎管狭窄症、腰肌劳损)85例,膝痹44例,其他病症(四肢关节疼、肌筋膜炎、劳损)13例。对照组肩痹症8例,颈椎病6例,腰痹症12例,膝痹7例,其他2例。
治疗组患者分别给予实施例1的药物组合物,将药物细粉用53。白酒调匀制成膏剂,将药膏涂在患者痛处,依次用柔和的摩法、推法及掌按揉法,按摩时力度均匀、柔和,由轻到重逐渐用力,力度及温度以患者能耐受为主,按摩3-5min后;采用透明薄膜覆盖药物15-20min,1次/天,20~30min/次。治疗7天为一疗程,连续治疗两个疗程。
对照组35例,包括男16例、女19例,平均年龄57.57±5.43岁,平均病程8.54±8.12月。对照组外用阳性对照药双氯芬酸二乙胺乳胶剂软膏,将该乳胶剂涂于患者患处,轻轻揉搓,使其渗透皮肤,一日3次。治疗7天为一疗程,连续治疗两个疗程。
比较评价治疗组和对照组患者在治疗前、治疗一个疗程(治疗7天)、治疗两个疗程(治疗14天)后的疼痛程度,并比较其总有效率,记录患者的一般生命体征、恶心呕吐、头痛头晕、皮肤过敏等不良反应。
1、所有患者采用疼痛视觉模拟评分(visual analogue scale,VAS)评估患者治疗前后的疼痛情况,根据疼痛程度不同分为0~10分:无痛为0分;轻度疼痛为≤3分,患者有疼痛但能正常生活;中度疼痛为>3~6分,疼痛持续出现,不能忍受,需要服用镇痛药物;重度疼痛为>6分,剧烈疼痛,需要镇痛药物,严重影响患者生活工作。
评定方法:在1张白纸上画1条直线,标注刻度表示评分(0~10分),分值越高表明疼痛程度越剧烈。患者在治疗前后根据自身疼痛情况在相应的刻度上做标记来表示疼痛强度,研究者准确记录数据。
2、疗效评定标准参照《中药新药临床研究指导原则》制定。显效,患处疼痛基本消失,功能明显改善;有效,患处疼痛明显缓解,功能有所改善;无效,疼痛症状无改善或加重,功能活动明显受限。
治疗总有效率=(显效例数+有效例数)/总例数×100%。
研究数据应用SPSS20.0软件进行统计学分析和处理,计数资料以例数或百分比表示,计量资料用x±s表示,采用卡方检验;组间比较用独立样本t检验,P<0.05为差异具有统计学意义。
3、研究结果
(1)VAS评分结果
治疗前,治疗组和对照组的VAS评分比较差异无统计学意义(P>0.05)。治疗7、14d后,2组VAS评分均低于治疗前,且治疗组VAS评分显著低于对照组,差异有统计学意义(P<0.05),结果见表1。与双氯芬酸二乙胺乳胶剂相比,本发明的药物组合物减轻患者患处疼痛效果更优。半数以上病人使用本发明药物治疗3-5天时,疼痛症状即可明显缓解或消失,具有起效快的优势。
表1
说明:*表示与治疗前比较(P<0.05);#表示与治疗7d后比较(P<0.05)。
(2)疗效评定结果(见表2)
治疗组显效147例,有效67例,无效6例,总有效率(97.27%)和显效率(66.82%);对照组显效13例,有效18例,无效4例,总有效率(88.57%)和显效率(37.14%)。与对照组的总有效率和显效率相比,治疗组的总有效率和显效率差异均有统计学意义(P<0.05),本发明的药物组合物治疗总有效率和显效率显著优于对照药物双氯芬酸二乙胺乳胶剂。
表2
治疗组和对照组患者在接受治疗期间,均未报告皮肤过敏等不良反应,本发明药物安全有效性良好。
实施例1-实施例3的药物组合物具有基本相同的活性、疗效和安全性。现以病例1-病例5示例实施例1-实施例3的药物组合物的用药安全有效性。
病例1:患者张某,男,46岁,2020年3月于医院门诊就诊。主诉腰部疼痛不适半年加重1个月,自述近两周应用外用药物治疗疼痛不减轻,症状未见好转并加重。门诊医师查体拍摄腰部CT后,诊断为“腰椎间盘突出症”,患者VAS评分7分。患者外用实施例3的药物组合物治疗2个疗程后,患者自述应用3天后腰痛症状即明显减轻,VAS评分3分。经治疗两周结束,患者疼痛各症消失而愈,VAS评分0分。
病例2:患者董某,女,57岁,2020年11月于医院门诊就诊。患者自述双膝疼痛病史3年,双膝关节疼痛、作冷,下肢酸楚,严重时行走困难,最近2个月疼痛加重,既往诊断为“双膝骨关节炎”,患者VAS评分9分。给予患者外用实施例1的药物组合物治疗2个疗程,治疗1疗程患者双膝疼痛症状缓解,VAS评分降为4分,连续治疗两个疗程已无明显疼痛及关节作冷,关节屈伸基本正常,行走无障碍,VAS评分降为1分。
病例3:患者李某,男,52岁,2020年8月于医院门诊就诊。主诉颈部不适近1年,5天前颈部及肩背部左侧出现疼痛,颈部活动受限,经社区医院按摩、拔罐治疗后,症状未见缓解。医师查体摄片X线检查:颈椎生理弯曲度变直,第4、5颈椎前后缘均可见骨赘形成,诊为“颈椎病”,VAS评分7分。患者外用实施例2的药物组合物治疗2个疗程,患者经治2天后即觉疼痛和颈部活动受限症状明显减轻,VAS评分降为2分。治疗两个疗程后,患者颈肩部疼痛、颈部活动受限症状完全消失,VAS评分降为0分。
病例4:焦某,男,28岁,2021年4月就诊,自述3天前打篮球时扭伤左膝出现肿痛,伤后外用药物喷雾和冷敷治疗未见效果,第2天肿痛症状加重,左下肢疼痛影响行走、左膝伸屈活动受限,VAS评分8分。门诊医师查体阅片后,诊断为软组织损伤,考虑左下肢肌肉损伤并左膝关节侧副韧带损伤。患者外用实施例3的药物组合物治疗一疗程后,患者疼痛明显减轻、肿胀轻度缓解,左膝伸屈功能明显好转,已可基本行走,VAS评分降为3分。连续治疗两个疗程后,患者的上各症状基本消失,膝关节功能恢复正常,VAS评分降为1分。
病例5:杨某,女,68岁,2021年6月就诊。主诉3年前因肩部劳累造成右肩损伤出现疼痛,后经治疗疼痛症状缓解。近两年右肩常出现隐痛,有时牵及右侧颈部也会出现疼痛。自述近3个月应用扶他林外搽和外用贴膏治疗,疼痛症状无法缓解,VAS评分7分。门诊医师查体阅片后诊断:右肩关节退变,考虑肩袖损伤。患者外用实施例2的药物组合物治疗1个疗程后,患者右肩隐痛基本消失,VAS评分降为2分。连续治疗2个疗程后,患者颈肩部的疼痛症状消失痊愈,VAS评分降为0分。
以上对本发明具体实施方式的描述并不限制本发明,本领域技术人员可以根据本发明作出各种改变或变形,只要不脱离本发明的精神,均应属于本发明权利要求保护的范围。
Claims (10)
1.一种高效缓解疼痛的药物组合物,以重量份计,组合物中含有当归10-30份、木瓜10-30份、赤芍10-30份、乳香10-30份、土鳖虫10-30份、苏木5-20份、红花5-20份、血竭0.1-5份、丁香5-20份、(木)芙蓉叶20-40份、金果榄20-40份、没药10-25份和煅自然铜20-40份。
2.如权利要求1所述的药物组合物,以重量份计,组合物中含有当归15-25份、木瓜15-25份、赤芍15-25份、乳香15-25份、土鳖虫15-25份、苏木8-15份、红花8-15份、血竭0.5-3份、丁香8-15份、(木)芙蓉叶25-35份、金果榄25-35份、没药15-20份和煅自然铜25-35份。
3.如权利要求1-2任一项所述的药物组合物,以重量份计,组合物中含有当归20份、木瓜20份、赤芍20份、乳香20份、土鳖虫20份、苏木10份、红花10份、血竭1份、丁香10份、(木)芙蓉叶30份、金果榄30份、没药18份和煅自然铜30份。
4.如权利要求1-3任一项所述的药物组合物,以重量份计,组合物中含有当归15份、木瓜15份、赤芍15份、乳香15份、土鳖虫15份、苏木5份、红花5份、血竭1份、丁香5份、(木)芙蓉叶20份、金果榄10份、没药15份和煅自然铜20份。
5.如权利要求1-4任一项所述的药物组合物,以重量份计,组合物中含有当归30份、木瓜30份、赤芍30份、乳香30份、土鳖虫20份、苏木10份、红花10份、血竭1份、丁香10份、(木)芙蓉叶30份、金果榄30份、没药18份和煅自然铜30份。
6.如权利要求1-5任一项所述的高效缓解疼痛的药物组合物的制备方法,以重量份计,组合物中含有当归10-30份、木瓜10-30份、赤芍10-30份、乳香10-30份、土鳖虫10-30份、苏木5-20份、红花5-20份、血竭0.1-5份、丁香5-20份、(木)芙蓉叶20-40份、金果榄20-40份、没药10-25份和煅自然铜20-40份,其制备包括下述步骤:将所需量的组分均匀混合后,研磨为细粉,即得。
7.如权利要求6所述的制备方法,将制得的药物组合物细粉临用前用溶剂调成膏剂或糊剂,将制得的膏剂或糊剂涂抹在患者痛处或患处,依次用柔和的摩法、推法、掌按揉法的任一种或其组合,按摩3-5min后,再用透明薄膜覆盖药物15-20min,1次/d,20~30min/次,其中,所述溶剂选自水、姜汁、醋、白酒的任一种。
8.如权利要求6-7任一项所述的制备方法,药物组合物细粉:溶剂的质量体积比为1:10-20。
9.如权利要求6-8任一项所述的制备方法,所述组合物为外用制剂。
10.如权利要求1-5任一项所述的药物组合物或如权利要求6-9任一项所述的制备方法制备得到的药物组合物用于制备防治或缓解疼痛或疼痛不适所致的相关病症或其并发症的药物中的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2023105270218 | 2023-05-11 | ||
CN202310527021 | 2023-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117018108A true CN117018108A (zh) | 2023-11-10 |
Family
ID=88641008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311060777.2A Pending CN117018108A (zh) | 2023-05-11 | 2023-08-22 | 一种高效缓解疼痛的药物组合物及其制备方法和其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117018108A (zh) |
-
2023
- 2023-08-22 CN CN202311060777.2A patent/CN117018108A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1626187A (zh) | 风湿骨痛药贴 | |
CN102670928B (zh) | 一种治疗颈椎病及腰椎病的膏药 | |
CN101062194B (zh) | 治疗骨病、骨折的药物及制备方法 | |
CN103239520B (zh) | 一种治疗骨性关节炎的回药膏及其制备方法 | |
CN101234153B (zh) | 治疗骨折的外用药物 | |
CN103690623B (zh) | 一种跌打损伤药酒 | |
CN103169822B (zh) | 滑膜炎回药膏及其制备方法 | |
CN1850227B (zh) | 一种治疗骨折的药物 | |
CN113842421A (zh) | 一种治疗颈椎病用的中药浓缩液及其制备方法和应用 | |
CN117018108A (zh) | 一种高效缓解疼痛的药物组合物及其制备方法和其应用 | |
CN113144165A (zh) | 一种主治类风湿关节炎的解凝除痹药散 | |
CN105395608A (zh) | 一种治疗骨裂中药组合物及其制备方法 | |
CN101195002B (zh) | 祛痛保健中药贴膏 | |
CN109966451A (zh) | 一种正骨止痛的中药组合物 | |
CN108904705A (zh) | 一种治疗绝经后女性慢性痛风性关节炎的中药组合物 | |
CN109010549A (zh) | 接骨祛风活血止痛膏及其制备方法 | |
CN103948870A (zh) | 治疗神经性头痛的中药制剂 | |
CN107929636A (zh) | 一种治疗疼痛的中药喷剂及其制备方法 | |
CN104606455B (zh) | 一种治疗腰肌劳损的药剂 | |
CN101954043A (zh) | 一种治疗骨质增生的药物及其制备方法 | |
CN106377615A (zh) | 一种治疗腰椎、颈椎增生和骨刺的中药组合物 | |
CN104984266A (zh) | 用于治疗骨质增生的中药组合物及其制备方法 | |
CN105853760A (zh) | 一种骨科膏药及其制备方法 | |
CN104435329A (zh) | 一种治疗跟骨高压症的中药组合物 | |
CN1120014C (zh) | 一种治疗骨质增生的中成药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |